Investigating the effect of Attentalin in children with hyperactivity attention deficit disorder

Investigating the effect of Attentalin on the severity of symptoms of hyperactivity/impulsivity in children with hyperactivity attention deficit disorder

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240520061849N1

Enrollment

108

Registered

2024-05-26

Start date

2024-06-21

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperactivity attention deficit disorder. Attention-deficit hyperactivity disorder, predominantly inattentive type

Interventions

Intervention 1: Intervention group: quick release methylphenidate (product of Porsina company) 5 mg once or twice a day + Attentalin syrup (product of Simorgh Daru Atar company) 10 cc twice a day. In

Eligibility

Sex/Gender

All

Age

6 Years to 9 Years

Inclusion criteria

Inclusion criteria: Patients with attention deficit hyperactivity disorder Informed consent of the patient's parents or legal guardian to participate in the study Children 6 to 9 years old

Exclusion criteria

Exclusion criteria: History of drug side effects after taking Attentalin

Design outcomes

Primary

Measure	Time frame
Score of symptoms of hyperactivity/impulsivity in Connors parent questionnaire. Timepoint: Measuring the severity of symptoms of hyperactivity/impulsivity at the beginning of the study (before the start of the intervention) and 8 weeks after taking attentalin. Method of measurement: Connors Parent Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTaiebeh Shoja

Arak University of Medical Sciences

T.shuja@arakmu.ac.ir+98 86 3313 4717

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026